CTNM (Contineum Therapeutics) Buyback Yield % : -87.14 (As of Apr. 24, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Contineum Therapeutics's current buyback yield was -87.14%.

Contineum Therapeutics Buyback Yield % Historical Data

The historical data trend for Contineum Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Buyback Yield % Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Buyback Yield %

-28.57

Contineum Therapeutics Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Buyback Yield %	Get a 7-Day Free Trial					-	-	-	-	-28.57

Competitive Comparison of Contineum Therapeutics's Buyback Yield %

For the Biotechnology subindustry, Contineum Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Contineum Therapeutics's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's Buyback Yield % falls into.

Save Embed

;

Save Embed

;

Contineum Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Contineum Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	108.211)	/	378.77575
	=	-28.57%

Contineum Therapeutics's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (0	+	108.211)		/	378.77575
	=	-28.57%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Contineum Therapeutics Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3565 General Atomics Court, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.